658 results match your criteria Prostate Cancer - Neoadjuvant Androgen Deprivation


Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.

Cancer Med 2021 May 1. Epub 2021 May 1.

Kotake Clinic, Osaka, Japan.

Background: We evaluated patient-reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally advanced prostate cancer (Pca).

Methods: A multicenter, randomized phase III trial enrolled 303 patients with locally advanced Pca. The patients were treated with 6 months (M) of ADT followed by 72 Gy of EBRT, and were randomly assigned to CADT or IADT after 14 M. Read More

View Article and Full-Text PDF

Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.

J Urol 2021 Apr 28:101097JU0000000000001831. Epub 2021 Apr 28.

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Purpose: Radiation refractory prostate cancer (RRPCa) is common and salvage cryotherapy for RRPCa is emerging as a viable local treatment option. However, there is a paucity of long-term data. The purpose of this study is to determine long-term outcomes following salvage cryotherapy for RRPca. Read More

View Article and Full-Text PDF

Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.

Prostate 2021 Jun 27;81(9):560-571. Epub 2021 Apr 27.

Key Lab of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China.

Background: The application of neoadjuvant docetaxel and androgen deprivation therapy before radical prostatectomy has been clinically recognized as beneficial for the overall and progression-free survival of patients with advanced prostate cancer. However, the mechanism underlying its clinical efficacy has not yet been reported.

Methods: We conducted a randomized comparative study on about 100 patients with high-risk localized prostate cancer. Read More

View Article and Full-Text PDF

Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy.

Phys Imaging Radiat Oncol 2021 Jan 24;17:117-123. Epub 2021 Feb 24.

Department of Radiation Sciences, Umeå University, Umeå, Sweden.

Background And Purpose: In locally advanced prostate cancer (PC), androgen deprivation therapy (ADT) in combination with whole prostate radiotherapy (RT) is the standard treatment. ADT affects the prostate as well as the tumour on multiparametric magnetic resonance imaging (MRI) with decreased PC conspicuity and impaired localisation of the prostate lesion. Image texture analysis has been suggested to be of aid in separating tumour from normal tissue. Read More

View Article and Full-Text PDF
January 2021

Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.

Eur Urol 2021 Apr 19. Epub 2021 Apr 19.

Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

Background: Intense neoadjuvant androgen deprivation therapy (ADT) before radical prostatectomy (RP) is an investigational approach to reduce recurrence rates in men with high-risk localized prostate cancer (PCa). The impact of germline DNA damage repair (gDDR) gene alterations on response to intense neoadjuvant ADT is not known.

Objective: To evaluate the prevalence of gDDR alterations among men with localized PCa at high risk of recurrence and evaluate their impact on response to intense neoadjuvant ADT. Read More

View Article and Full-Text PDF

Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis.

Clin Genitourin Cancer 2021 Feb 24. Epub 2021 Feb 24.

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address:

Background: The study aimed to investigate the efficacy and safety outcomes in hormone-sensitive oligometastatic prostate cancer (OMPC) patients treated with docetaxel-based neoadjuvant chemohormonal therapy (NCHT) prior to radical prostatectomy (RP) compared with direct RP and standard androgen deprivation therapy (ADT) alone using propensity score match (PSM) analysis.

Patients And Methods: A single-center, prospective, three-arm study was conducted with hormone-sensitive OMPC patients. Eligible patients (N = 130) were divided into three groups-NCHT, RP, and standard treatment (ST)-and received their respective treatments. Read More

View Article and Full-Text PDF
February 2021

Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.

Eur Urol 2021 Mar 27. Epub 2021 Mar 27.

Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, MD, USA. Electronic address:

Background: Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) have shown lower rates of recurrence among patients with minimal residual disease after treatment. The molecular features that distinguish exceptional responders from poor responders are not known. Read More

View Article and Full-Text PDF

Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance).

J Urol 2021 Mar 29:101097JU0000000000001716. Epub 2021 Mar 29.

Memorial Sloan Kettering Cancer Center, New York, New York.

Purpose: Men with low serum testosterone at the time of prostate cancer diagnosis are frequently considered to have more aggressive disease. We examined treatment outcomes in men with clinically localized high-risk cancer to determine if baseline testosterone level identified men at higher risk for cancer progression after treatment.

Materials And Methods: Alliance/CALGB 90203 randomized men with clinically localized high-risk prostate cancer to radical prostatectomy alone or neoadjuvant chemohormonal therapy and radical prostatectomy. Read More

View Article and Full-Text PDF

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.

Prostate 2021 May 23;81(7):418-426. Epub 2021 Mar 23.

Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.

Background: Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)-targeted therapies as a result of persistent intraprostatic androgens arising through upregulation of steroidogenic enzymes. Therefore, we sought to evaluate clinical effects of neoadjuvant indomethacin (Indo), which inhibits the steroidogenic enzyme AKR1C3, in addition to combinatorial anti-androgen blockade, in men with high-risk PC undergoing radical prostatectomy (RP).

Methods: This was an open label, single-site, Phase II neoadjuvant trial in men with high to very-high-risk PC, as defined by NCCN criteria. Read More

View Article and Full-Text PDF

Inverse Stage Migration in Radical Prostatectomy-A Sustaining Phenomenon.

Front Surg 2021 1;8:612813. Epub 2021 Mar 1.

Department of Urology, University Hospital Frankfurt, Frankfurt, Germany.

To investigate temporal trends in prostate cancer (PCa) radical prostatectomy (RP) candidates. Patients who underwent RP for PCa between January 2014 and December 2019 were identified form our institutional database. Trend analysis and logistic regression models assessed RP trends after stratification of PCa patients according to D'Amico classification and Gleason score. Read More

View Article and Full-Text PDF

Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.

J Urol 2021 Mar 8:101097JU0000000000001702. Epub 2021 Mar 8.

Dana-Farber Cancer Institute, Boston, Massachusetts.

Purpose: This multicenter randomized phase 2 trial investigates the impact of intense androgen deprivation on radical prostatectomy pathologic response and radiographic and tissue biomarkers in localized prostate cancer (NCT02903368).

Materials And Methods: Eligible patients had a Gleason score ≥4+3=7, PSA >20 ng/mL or T3 disease and lymph nodes <20 mm. In Part 1, patients were randomized 1:1 to apalutamide, abiraterone acetate, prednisone and leuprolide (AAPL) or abiraterone, prednisone, leuprolide (APL) for 6 cycles (1 cycle=28 days) followed by radical prostatectomy. Read More

View Article and Full-Text PDF

Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review.

Cancers (Basel) 2021 Feb 12;13(4). Epub 2021 Feb 12.

Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai 400012, India.

Background: Radiotherapy (RT) is an established, potentially curative treatment option for all risk constellations of localized prostate cancer (PCA). Androgen deprivation therapy (ADT) and dose-escalated RT can further improve outcome in high-risk (HR) PCA. In recent years, shorter RT schedules based on hypofractionated RT have shown equal outcome. Read More

View Article and Full-Text PDF
February 2021

Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.

Urol Int 2021 25;105(5-6):436-445. Epub 2021 Feb 25.

Department of Urology, Rostock University, Rostock, Germany.

Background: Observational studies generate information on real-world therapy and complement data from prospective randomized trials. LEAN is an open-label, non-interventional, multi-centre, German cohort study on leuprorelin in routine clinical practice.

Objectives: To extend knowledge on the use, effectiveness, and tolerability of HEXAL/Sandoz leuprorelin (in this article, the term Leuprone® HEXAL® covers Leuprorelin Sandoz® as well) solid implant in patients with prostate cancer (PCa) in a real-world setting. Read More

View Article and Full-Text PDF
February 2021

Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change.

Cancer Treat Res Commun 2021 Feb 6;27:100331. Epub 2021 Feb 6.

RadiationOncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Purpose: To adapt the management of prostate malignancy in response to the COVID-19 pandemic.

Methods: In according to the recommendations of the European Association of Urology, we have developed practical additional document on the treatment of prostate cancer.

Results: Low-Risk Group Watchful Waiting should be offered to patients >75 years old, with a limited life expectancy and unfit for local treatment. Read More

View Article and Full-Text PDF
February 2021

Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer.

Int J Radiat Oncol Biol Phys 2021 Jan 30. Epub 2021 Jan 30.

Radiation Medicine Program, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada. Electronic address:

Purpose: Two phase 3 randomized controlled trials (OTT-0101, RTOG-9413) and a meta-analysis have shown an impact of sequencing of androgen deprivation therapy (ADT) and radiation therapy on oncologic outcomes in prostate cancer (PCa). However, the impact of sequencing strategy on health-related quality of life (HR-QoL) is unclear. Here, we present the patient-reported HR-QoL outcomes from the OTT-0101 study. Read More

View Article and Full-Text PDF
January 2021

Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.

J Urol 2021 Jun 27;205(6):1689-1697. Epub 2021 Jan 27.

Dana-Farber Cancer Institute, Boston, Massachusetts.

Purpose: We report on the post-radical prostatectomy outcomes of patients enrolled in 3 randomized, multicenter, clinical trials of intense neoadjuvant androgen deprivation therapy prior radical prostatectomy.

Materials And Methods: All patients included were enrolled in trials evaluating intense androgen deprivation therapy followed by radical prostatectomy. The primary end point was time to biochemical recurrence, defined as the time from radical prostatectomy to prostate specific antigen >0. Read More

View Article and Full-Text PDF

Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study.

Cancer Causes Control 2021 Mar 4;32(3):261-269. Epub 2021 Jan 4.

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.

Purpose: To investigate men's experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial.

Methods: A longitudinal qualitative interview study was embedded in the ProtecT RCT. Sixteen men with clinically LPCa who underwent EBRT in ProtecT were purposively sampled to include a range of socio-demographic and clinical characteristics. Read More

View Article and Full-Text PDF

Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.

Int J Clin Oncol 2021 Apr 2;26(4):744-752. Epub 2021 Jan 2.

Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.

Background: The salvage treatments for biochemical recurrence (BCR) include local external beam radiation therapy (RT) and systemic androgen-deprivation therapy (ADT).

Methods: We reviewed patients who underwent radical prostatectomy (RP) and developed BCR at three institutions. After excluding patients whose nadir prostate-specific antigen (PSA) was higher than 0. Read More

View Article and Full-Text PDF

Neoadjuvant Therapy in High-Risk Prostate Cancer.

Indian J Urol 2020 Oct-Dec;36(4):251-261. Epub 2020 Oct 1.

USC Institute of Urology, Keck Medical Center of USC, University of Southern California, Los Angeles, California, USA.

High-risk prostate cancer (PCa) is associated with higher rates of biochemical recurrence, clinical recurrence, metastasis, and PCa-specific death, compared to low-and intermediate-risk disease. Herein, we review the various definitions of high-risk PCa, describe the rationale for neoadjuvant therapy prior to radical prostatectomy, and summarize the contemporary data on neoadjuvant therapies. Since the 1990s, several randomized trials of neoadjuvant androgen deprivation therapy (ADT) have consistently demonstrated improved pathological parameters, specifically tumor downstaging and reduced extraprostatic extension, seminal vesicle invasion, and positive surgical margins without improvements in cancer-specific or overall survival. Read More

View Article and Full-Text PDF
October 2020

Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer.

Adv Radiat Oncol 2020 Nov-Dec;5(6):1213-1224. Epub 2020 Jun 28.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Purpose: The Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial reported overall survival benefits for prostate-directed radiation therapy (PDRT) in low-burden metastatic prostate cancer. Oligometastasis-directed radiation therapy (ORT) improves androgen deprivation therapy (ADT)-free and progression-free survivals. Comprehensive PDRT + ORT to all detectable metastases may offer benefit for de novo oligometastatic prostate cancer (DNOPC) and is under prospective study; given few available benchmarks, we reviewed our institutional experience. Read More

View Article and Full-Text PDF

Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.

Eur Urol 2021 02 3;79(2):298-306. Epub 2020 Dec 3.

The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address:

Background: Ductal prostate adenocarcinoma (DAC) is a rare, aggressive, histologic variant of prostate cancer that is treated with conventional therapies, similar to high-risk prostate adenocarcinoma (PAC).

Objective: To assess the outcomes of men undergoing definitive therapy for DAC or high-risk PAC and to explore the effects of androgen deprivation therapy (ADT) in improving the outcomes of DAC.

Design, Setting, And Participants: A single-center retrospective review of all patients with cT1-4/N0-1 DAC from 2005 to 2018 was performed. Read More

View Article and Full-Text PDF
February 2021

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.

J Clin Oncol 2021 Jan 4;39(2):136-144. Epub 2020 Dec 4.

Medical College of Wisconsin, Milwaukee, WI.

Purpose: There remains a lack of clarity regarding the influence of sequencing of androgen deprivation therapy (ADT) and radiotherapy (RT) on outcomes in prostate cancer (PCa). Herein, we evaluate the optimal sequencing of ADT with prostate-directed RT in localized PCa.

Methods: MEDLINE (1966-2018), Embase (1982-2018), ClinicalTrials. Read More

View Article and Full-Text PDF
January 2021

CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.

Prostate 2021 Feb 1;81(2):127-134. Epub 2020 Dec 1.

Department of Urology, The James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Background: The purpose of this study is to assess the body composition changes in men with recently diagnosed oligometastatic prostate cancer following neoadjuvant chemohormonal therapy. Further, we evaluated whether CT-based body composition parameters are associated with biochemical recurrence or imaging progression.

Material And Methods: Recently diagnosed castration-naïve oligometastatic prostate cancer patients who received neoadjuvant docetaxel chemotherapy and androgen deprivation treatment (ADT) before prostatectomy and consolidation of local and oligometastatic disease (total eradication therapy), as part of a phase-II prospective clinical trial were included. Read More

View Article and Full-Text PDF
February 2021

Safety and Efficacy of Ultra-hypofractionation in Node-positive Prostate Cancer.

Clin Oncol (R Coll Radiol) 2021 Mar 16;33(3):172-180. Epub 2020 Nov 16.

Department of Radiation Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India.

Aims: The safety and efficacy of stereotactic body radiotherapy (SBRT) in localised prostate cancer are now established through phase III randomised trials. Its utility in node-positive prostate cancer is restricted due to a lack of controlled studies specifically addressing this subgroup. Herein we report the safety and efficacy of SBRT in this subgroup. Read More

View Article and Full-Text PDF

Can Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study.

J Urol 2021 Apr 18;205(4):1082-1089. Epub 2020 Nov 18.

Department of Urology, Affiliated Drum Tower hospital, Medical School of Nanjing University, Nanjing, China.

Purpose: We explored the role of Ga-PSMA-11 positron emission/computerized tomography as a predictor of pathological response to neoadjuvant androgen deprivation therapy combined with abiraterone for high risk prostate cancer.

Materials And Methods: A total of 45 patients with localized high risk prostate cancer who had serial Ga-PSMA-11 positron emission tomography/computerized tomography scans before and after 6 months of androgen deprivation therapy plus abiraterone neoadjuvant treatment followed by radical prostatectomy were included in this study. Complete pathological response or minimal residual disease <5 mm on whole mount histopathology was defined as favorable pathological response. Read More

View Article and Full-Text PDF

Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.

Pharmacol Res 2021 Feb 14;164:105305. Epub 2020 Nov 14.

Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China. Electronic address:

On account of incurable castration-resistant prostate cancer (CRPC) inevitably developing after treating with androgen deprivation therapy, it is an urgent need to find new therapeutic strategies. Flubendazole is a well-known anti-malarial drug that is recently reported to be a potential anti-tumor agent in various types of human cancer cells. However, whether flubendazole could inhibit the castration-resistant prostate cancer has not been well charified. Read More

View Article and Full-Text PDF
February 2021

Proton Therapy for Localized Prostate Cancer: Long-Term Results From a Single-Center Experience.

Int J Radiat Oncol Biol Phys 2021 Mar 10;109(4):964-974. Epub 2020 Nov 10.

Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan.

Purpose: Although proton therapy is controversial, it has been used to treat localized prostate cancer over the past 2 decades. The purpose of this study is to examine the long-term efficacy and toxicity of proton therapy for localized prostate cancer.

Methods And Materials: This was a retrospective observational study of 2021 patients from 2003 to 2014 at a single institution. Read More

View Article and Full-Text PDF

Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer.

PLoS One 2020 6;15(11):e0241636. Epub 2020 Nov 6.

Department of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.

Background: This study aimed to explain the dynamics of prostate-specific antigen (PSA) levels in patients with prostate cancer who were treated with carbon ion radiotherapy (CIRT) and neoadjuvant androgen-deprivation therapy (ADT).

Methods: Eighty-five patients with intermediate-risk prostate cancer who received CIRT and neoadjuvant ADT from December 2015 to December 2017 were analyzed in the present study. The total dose of CIRT was set at 51. Read More

View Article and Full-Text PDF
January 2021

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.

Clin Cancer Res 2021 Jan 6;27(2):429-437. Epub 2020 Oct 6.

Genitourinary Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Purpose: For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the potential to better define characteristics of response and resistance. Read More

View Article and Full-Text PDF
January 2021